Synopsys, Inc. (NASDAQ:SNPS – Get Free Report) insider Geus Aart De sold 25,000 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $445.55, for a total transaction of $11,138,750.00. Following the completion of the sale, the insider directly owned 120,421 shares in the company, valued at $53,653,576.55. This trade represents a 17.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Synopsys Trading Down 0.7%
Shares of NASDAQ:SNPS traded down $3.02 during trading hours on Monday, hitting $439.59. 1,680,894 shares of the company’s stock traded hands, compared to its average volume of 1,998,091. The firm has a market capitalization of $84.24 billion, a P/E ratio of 77.67, a price-to-earnings-growth ratio of 2.42 and a beta of 1.23. The business has a fifty day moving average price of $416.64 and a 200-day moving average price of $440.14. Synopsys, Inc. has a 1 year low of $366.00 and a 1 year high of $615.79. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.34 and a quick ratio of 1.24.
Synopsys (NASDAQ:SNPS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 26th. The semiconductor company reported $3.91 earnings per share for the quarter, topping the consensus estimate of $3.67 by $0.24. Synopsys had a return on equity of 6.24% and a net margin of 11.43%.The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.44 billion. During the same period in the prior year, the business posted $3.39 earnings per share. The company’s revenue for the quarter was up 42.4% on a year-over-year basis. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. Equities analysts expect that Synopsys, Inc. will post 11.03 earnings per share for the current year.
Institutional Trading of Synopsys
Analyst Ratings Changes
A number of equities analysts have commented on the stock. BNP Paribas Exane upped their target price on shares of Synopsys from $425.00 to $450.00 and gave the stock an “underperform” rating in a research note on Thursday, May 28th. Piper Sandler raised shares of Synopsys from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $450.00 to $550.00 in a research note on Tuesday, June 23rd. KeyCorp reiterated an “overweight” rating on shares of Synopsys in a report on Wednesday, August 19th. Morgan Stanley reduced their price objective on Synopsys from $525.00 to $500.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 19th. Finally, Berenberg Bank set a $633.00 target price on Synopsys in a research report on Wednesday, May 27th. Twelve analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Synopsys has an average rating of “Moderate Buy” and an average target price of $561.28.
Read Our Latest Research Report on Synopsys
Synopsys Company Profile
Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.
In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.
Recommended Stories
- Five stocks we like better than Synopsys
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
